Intracellular purine turnover is mainly oriented to preserving the level of triphosphate nucleotides, fundamental molecules in vital cell functions that, when released outside cells, act as receptor signals. Conversely, high levels of purine bases and uric acid are found in the extracellular milieu, even in resting conditions. These compounds could derive from nucleosides/ bases that, having escaped to cell reuptake, are metabolized by extracellular enzymes similar to the cytosolic ones. Focusing on purine nucleoside phosphorylase (PNP) that catalyzes the reversible phosphorolysis of purine (deoxy)-nucleosides/ bases, we found that it is constitutively released from cultured rat C6 glioma cells into the medium, and has a molecular weight and enzyme activity similar to the cytosolic enzyme. Cell exposure to 10 lM ATP or guanosine triphosphate (GTP) increased the extracellular amount of all corresponding purines without modifying the levels/activity of released PNP, whereas selective activation of ATP P2Y 1 or adenosine A 2A metabotropic receptors increased PNP release and purine base formation. The reduction to 1% in oxygen supply (2 h) to cells decreased the levels of released PNP, leading to an increased presence of extracellular nucleosides and to a reduced formation of xanthine and uric acid. Conversely, 2 h cell re-oxygenation enhanced the extracellular amounts of both PNP and purine bases. Thus, hypoxia and re-oxygenation modulated in opposite manner the PNP release/activity and, thereby, the extracellular formation of purine metabolism end-products. In conclusion, extracellular PNP and likely other enzymes deputed to purine base metabolism are released from cells, contributing to the purinergic system homeostasis and exhibiting an important pathophysiological role.
metabotropic receptors or cyclic nucleotides (cAMP or cGMP)]. Moreover, a paramount body of evidence has been accumulated over the last four decades about the role of purine nucleotides and nucleosides as transmitters or modulators interacting with their own specific receptors (Burnstock 2014; Sheth et al. 2014) .
To meet the highly dynamic requirements for purines in dividing, differentiating, and fully differentiated cells during development and throughout life, there is a well-coordinated metabolic cycle assuring the maintenance of the pool of intracellular purines as the result of de novo synthesis and salvage pathways ; Volont e and D'Ambrosi 2009). Many studies investigated the presence and the activity of intracellular enzymes deputed to purine metabolism and on their significance in relation to the administration of purine compounds as cytotoxic drugs in cancer (e.g., see Galmarini et al. 2002; Seetulsingh-Goorah 2006; Ipata and Tozzi 2013; Składanowski 2013; Panayiotou et al. 2014) . Other work has focused on extracellular enzymes linked to the plasma membranes, such as the ecto-nucleotidases (Zimmermann et al. 2012) , a family of enzymes degrading nucleoside tri-, di-, and monophoshates into adenosine (ADO) and guanosine (GUO), and the ecto-adenosine deaminase that converts ADO into inosine (INO) (Yegutkin 2008) . It was also demonstrated that specific carriers, deputed to resume extracellular purine nucleosides Ritzel et al. 2001) , are present in cell membranes (Young et al. 2008) , the direction of this flux mostly depending on the extra-or intracellular concentrations of these compounds (Plagemann and Woffedin, 1988; Ritzel et al. 2001) . The existence of specific carriers for the transport of purine bases such as hypoxanthine (HYPO) and guanine (GUA) inside/outside the cells has been repeatedly reported de Koning and Diallinas 2000; Bone and Hammond 2007) . Thus, it is conceivable that purine bases in the extracellular environment may derive from the activity of enzymes present at extracellular level and deputed to the metabolism of nucleosides, whereas only in conditions of intracellular excess they may derive from the intracellular compartment. So far, the existence of these extracellular enzymes was often postulated without any sure experimental evidence. They have been found in biological body fluids (Pettengill et al. 2013; L opez-Cruz et al. 2014; Giuliani et al. 2016) , where their presence was generally ascribed to cell death or membrane alterations as a result of tissue damages or cancer (Brass and Mody 1995; Roberts et al. 2004) .
In an attempt to shed light on these aspects, we initially focused on purine nucleoside phosphorylase (PNP, EC 2.4.2.1) that is commonly considered a cytoplasmic enzyme in prokaryotic and eukaryotic organisms (WielgusKutrowska et al. 2014) . A localization in mitochondria of bovine liver (Haag and Lewis 1994) has also been reported, although for its several unique properties mitochondrial PNP is considered to be a different protein from the cytosolic one.
PNP catalyzes the reversible phosphorolysis of purine nucleosides (INO and GUO) to the corresponding purine bases (HYPO and GUA) and ribose-1-phospate in the presence of inorganic orthophosphate (Pi) as a second substrate. However, inside cells, phosphorolysis is favored over nucleoside synthesis as it is coupled to the activity of other two downstream enzymes such as xanthine oxidase and hypoxanthine-guanine phosphoribosyltransferase leading to the oxidation and phosphoribosylation of the liberated purine bases (Bzowska et al. 2000) . PNP is widely expressed in mammalian tissues as a trimeric enzyme of approximately 90 000 Da (Rubio 1974; de Azevedo et al. 2003) . In humans, the highest activity of this enzyme has been found in peripheral granulocytes and lymphocytes (Carson et al. 1977) . Accordingly, lack of PNP expression causes a severe immune-deficiency syndrome (Spaapen et al. 1983; Fairbanks et al. 1990 ) that is associated with incomplete cerebral development and mental retardation in humans (Simmonds et al. 1987; Markert1991; Tam and Leshner 1995) . Indeed, PNP is present also in brain where its localization has been confined within glial cells, mainly in astrocytes (VanReempts et al. 1988; Castellano et al. 1990 ). Based on these findings, here we wanted to better investigate whether PNP was actually released from glial cells using rat C6 glioma cells as experimental model. We also tried to characterize the activity of this extracellular enzyme and its modulation in different experimental conditions.
Materials and methods

Chemicals and materials
Cell culture media, sera, and antibiotics were usually obtained from Life Technologies Italia (Monza, Italy), cell culture dishware from Becton Dickinson Falcon TM (Falcon, Becton Dickinson, Franklin Lakes, NJ, USA), and reagents and standards from Sigma-Aldrich (Milan, Italy).
Cell cultures and treatments
Rat glioma C6 cell line (ECACC, RRID: CVCL_0194) was purchased from Sigma Aldrich and cultured in Dulbecco's modified Eagle's medium with 5% heat-inactivated fetal bovine serum, 100 U/mL penicillin, and 100 mg/mL streptomycin at 37°C under humidified atmosphere and 5% CO 2 . For the experiments, cells were seeded onto 100 mm dishes at a cell density of 3 9 10 6 cells/dish and were used after 4 days.
Experimental protocols
Cultures, rinsed twice with Krebs-HEPES buffer (15 m M HEPES, pH 7.4,120 mM NaCl, 4 mM KCl, 1.2 mM MgSO 4 , 1 mM CaCl 2 , and 10 mM D-glucose), were fed with the same fresh buffer and kept for 30 min in standard condition (37°C; 5% CO 2 ). Then 2.5 lM ADO combined with 0.125 lM (3.6 lCi/mL) of [ 3 H]ADO (specific activity 29 Ci/mmol; Movarek Biochemicals, Brea, CA, USA) or 2.5 lM GUO combined with 0.675 lM of [ 3 H]GUO (3.6 lCi/mL) (specific activity 5.3 Ci/mmol; Movarek Biochemicals) was added and cells were incubated for 30 min. Subsequently, cells were rapidly washed twice with the same buffer and maintained in this medium in standard condition (37°C, 5% CO 2 ) up to the end of the experiment, except for the experiments carried out in hypoxic conditions. In this case, cells were placed for 2 h in a modular incubator chamber (Billups-Rothemberg Inc., Del Mar, CA, USA) and flushed with a gas mixture containing 1% O 2 and 5% CO 2 with the balance being N 2 . Then, cells, after medium replacement, were returned to normal oxygen conditions for a further 2 h. When used, drugs were added to the medium 1 h after the end of the incubation with labeled ADO or GUO and kept up to the end of the experiments, whereas purine receptor antagonists were added 30 min before the respective agonists.
Sample preparation for the evaluation of purine and PNP To evaluate the amounts of purines released from C6 cells, the medium was collected at the end of each experiment, except for hypoxia condition in which aliquots of medium were withdrawn at the end of both hypoxia (2 h) and re-oxygenation (2 h) periods. All medium samples were immediately heat inactivated for 5 min at 70°C to prevent any further metabolic degradation of released purines. After centrifugation, the supernatant, filtered through 0.2 lm filters (Millipore, Vimodrone, Italy), was stored at À80°C until HPLC analysis. For cytosolic purine measurement, after medium removal, perchloric acid (0.4 M) was added to the culture plates to favor cell lysis and to block enzyme reactions. Then cells were scraped and the precipitated material was removed by centrifugation (10 000 g, 5 min, 4°C). The resulting supernatant was neutralized with 0.1 M KOH, centrifuged again, and filtered with 0.2 lm filters (Millipore). Samples were stored at À20°C until assayed.
For the assessment of PNP, all procedures were carried out at 0-4°C. Aliquots (250 lL) of medium from four sister cultures were pooled at each time point indicated in the figures. After the addition of protease inhibitor cocktail (1% of final volume; Sigma Aldrich), samples were placed in suitable devices (Amikon Ultra 2 mL, cutoff 10 K; Merck Millipore, Darmstadt, Germany) by which, following the manufacturer's instructions, PNP present in the medium was concentrated by reducing the starting volume down to about 40 lL. These samples were stored at À80°C until assayed.
Moreover, at the end of each experiment and after medium removal, cells were washed twice with phosphate-buffered saline (PBS), scraped in lysis buffer (5 mM HEPES pH 8.5, 2 mM EDTA, and protease inhibitor cocktail), and sonicated. After centrifugation (1000 g, 10 min), the pellet was resuspended and again centrifuged (11 000 g, 20 min). Then, the supernatants were pooled and centrifuged (100 000 g, 30 min). The final supernatant (cytosol) as well as the pellet (plasma membrane), which was resuspended in a buffer suitable for western blotting, were stored at À80°C until the appropriate assays to determine PNP presence.
HPLC methods for determining purine contents and PNP activity Purine compounds were assayed by an Agilent 1100 series HPLC system equipped with a diode array detector (Agilent Technologies, Santa Clara, CA, USA). Separations were performed as previously reported (Giuliani et al. 2012 ) using a reverse-phase analytical column (LiChrospher 100 RP-18 5 lm in LiChroCART 125-4, Merck). A 15-min linear gradient system (constant flow rate: 1.5 mL/min) was used from 100% of buffer A (60 mM KH 2 PO 4 and 5 mM tetrabutylammonium phosphate, pH 6.0) to 100% of Buffer B (30% methanol plus 70% buffer A). The UV detection of unlabeled purines was performed at 254 nm except for uric acid (UAc) at 290 nm. Different compounds were identified and quantified by comparison with pure external standards. As some purine compounds were occasionally undetectable or under their limits of quantification, the HPLC system was equipped with an online radiochemical detector (FLO-ONE 500 TR, Packard Instruments) that, connected in series, allowed the simultaneous determination of unlabeled and labeled compounds, improving the instrument's sensitivity and the results obtained from the same chromatographic run. To measure labeled purines, liquid scintillation cocktail (Ultima-FloM, PerkinElmer) was pumped at 3 mL/ min, mixed continuously with the HPLC eluate, and passed through a 500 lL detector flow cell. After background radioactivity subtraction, radio-chromatograms were integrated and the radioactivity associated with each HPLC-identified compound was measured and converted into moles based on the specific activity of labeled ADO or GUO, used as tracers. Using the combined UV and radiochemical detection, we found that labeled nucleosides, taken up by the cells during the incubation period, underwent an extensive intracellular metabolism quickly leading to radioactivity distribution. For each purine compound, the percentage of labeled compound versus the total (labeled plus unlabeled) amount of the same compound was fairly constant and corresponding to 0.05%. Thus, after measuring the concentration of extracellular tritiated compounds, we used this percentage to calculate the total amount of each purine compound in the milieu.
However, as tritium labeling of ADO or GUO was linked to the carbon atom number 8 and/or 2 of the molecule and was lost when XAN was converted into UAc, the amount of UAc was measured only by the UV-DAD detector.
The PNP activity was evaluated by the conversion of the substrate GUO into its product GUA. The enzymatic reaction mixture was composed of 50 mM HEPES, pH 7.0, 50 mM inorganic phosphate (Pi) used as co-substrate plus a fixed aliquot of concentrated medium or cytosolic sample. The enzyme reaction started by the addition of varying concentrations of GUO. The mixture was incubated by shaking at 37°C for 15 min. The reaction was stopped by heating the mixture at 70°C for 5 min and the precipitated proteins were removed by centrifugation. The supernatant was filtrated with 0.2 lm filters (Millipore) before injection in the HPLC system. HPLC analysis was carried out following a recently published procedure (Giuliani et al. 2016) . In this case, the Agilent HPLC was equipped with a thermostated column compartment, a diode array detector, and a fluorescence detector (Agilent Technologies). Separation was achieved by a Phenomenex Kinetex pentafluorophenyl (5 lm pore size, 100 A particle size, 250 9 4.6 mm) analytical column (Phenomenex INC, Castelmaggiore, Bologna, Italy) kept at 35°C and applying a 15-min non-linear gradient (flow rate: 1 mL/min). The fluorescent GUO and GUA were monitored at an excitation wavelength of 260 nm and an emission wavelength of 375 nm, whereas the non-fluorescent compounds at 254 nm. All substances were identified and quantified by comparison with pure external standards. PNP activity was expressed as mU/mL medium, being 1 unit (U) of PNP, the amount of enzyme necessary to produce 1 lmol of GUA from GUO per min.
Lactate dehydrogenase assay
Lactate dehydrogenase (LDH) activity was determined by the CytoTox 96 Non-Radioactive Cytotoxicity Assay (Promega Italia, Milan, Italy). Cells were seeded (3 9 10 3 cells/well) in 96-well plates and grown for 4 days. Then, after medium replacement with Krebs-HEPES buffer, cells were incubated in standard condition at different times. Afterward, media were collected and cells in the plate were incubated (37°C, 5% CO 2 ) for 45 min with lysis solution (cat. #G182, Promega), indicated as appropriate by the assay manufacturer, and centrifuged at 250 g for 4 min. Subsequently, 50 lL aliquots from all media and wells were transferred to a new 96-well plate, and 50 lL of substrate buffer consisting of 0.7 mM piodonitrotetrazolium Violet, 50 mM L-lactic acid, 0.3 mM phenazine methoxysulfate, 0.4 mM NAD, and 0.2 M Tris-HCl pH 8.0 was added. The assay plate was covered with foil to protect it from light and incubated at 20-24°C for 30 min. Reaction was stopped by adding 50 lL/well of stop solution. The absorbance was measured spectrophotometrically at 490 nm and the results were expressed as a percentage of total LDH released from the positive control consisting of cells treated with 25 lL of 10% Nonidet P-40 (NP-40) and calculated as follows: (medium absorbance value -white absorbance value)/(medium absorbance + lysate absorbance) 9 100. All reagents were from Promega Italia.
Small interfering RNA knockdown of PNP expression PNP expression was knocked down with PNP small interfering RNA which was designed and synthesized by Dharmacon Research Inc. (Lafayette, CO, USA) based on rat PNP (Gene Accession Number: AA858647). Eighty microliters (20 lM) siRNA (GGAATGCTCTCCATAAGAA) were diluted in 95 lL optimem and incubated for 5 min at 20-24°C; at the same time 3 lL oligofectamine was diluted in 15 lL optimem and incubated for 5 min. Then, oligofectamine was added to siRNA and this mixture was incubated for a further 30 min at 20-24°C. The final solution was added to 24 h serum-starved cells for a period of 24 h and then total RNA was prepared for RT-PCR. A scrambled sequence was used as siRNA-negative control.
RT-PCR analysis
Total RNA was isolated from C6 glioma cells by using Trizol TM reagent (Thermo Fisher, Waltham, MS, USA) according to the manufacturer's recommendations. Prior to RT-PCR, the RNA was treated with 1 unit ribonuclease-free deoxyribonuclease (Roche, Italy) per microgram RNA to remove any genomic contaminants.
Complementary DNA (cDNA) was synthesized from 10 ug of total RNA by using RETROscript TM (Ambion Inc., Austin, TX, USA). Oligonucleotide amplification primers were designed from the published sequences (Accession Number AA858647): sense primer 5 0 -AAATCCAAGAGGTATGGGGT-3 0 , antisense 5 0 -ACAACAA CTTGGTGAAGGCCAG-3 0 . RT-PCR was conducted as follows:
94°C for 5 min, 28 cycles of 94°C for 1 min, 55°C for 1 min, and 72°C for 1 min. The final elongation was conducted for 10 min at 72°C. Reactions were also conducted without the reverse transcriptase step as a control for genomic DNA contamination in the RNA sample. Amplification products (497 bp) were resolved by agarose (1.5%) gel electophoresis; bands were excised and eluted from the gel, purified, and sequenced. Three RNA samples from each independent culture seeding were analyzed by RT-PCR with identical results.
Western blot analysis PNP protein expression was analyzed in samples of cytosol, plasma membrane, and culture medium of C6 glioma cells, removed at different time points as described in a previous section. 
Results
Conversion of INO and GUO into HYPO and GUA, respectively, outside the rat C6 glioma cells It is known that cells are provided with a large amount of intracellular adenine-based nucleotides and that, also in resting condition, they release ATP, which through a rapid breakdown by extracellular enzymes is converted into metabolites detectable outside the cells. Also GTP is released simultaneously to ATP and guanine-based derivatives are found in the extracellular medium, from glial cells at least (Ciccarelli et al. 1999) . Here, we show that rat C6 glioma cells behave in a similar way. At rest, the levels of triphosphate nucleotides, inside the cells, were about 10-or 100-fold higher than those of the corresponding nucleosides or purine bases, respectively. Conversely, outside the cells, the levels of HYPO, GUA, and mainly of XAN and UAc, the last two compounds being common to both adenine-and guanine-based purines, exceeded the nucleotide levels by many times (Table 1) . Cell exposure to a mixture of dipyridamole (10 lM) plus dilazep (10 lM), recognized as able to restrain the activity of nucleoside/nucleobase carriers across cell membrane (Robillard et al. 2008) , did not affect the amount and distribution of intracellular purines, whereas the extracellular levels of nucleosides were significantly increased as well as those of HYPO, GUA, and XAN (Table 1 ). These findings indicated that, in basal condition, purine bases are formed outside the cells. Starting from this evidence, we investigated whether the formation of extracellular HYPO and GUA was caused by the activity of PNP, possibly released into the culture medium from the same cells.
Intracellular localization of PNP and its release in the culture medium from rat C6 glioma cells The western blot analysis of samples from C6 cell cytosol and membranes as well as from extracellular medium removed after 6 h ( Fig. 1a1) pointed out the presence of a single isoform of the enzyme, of approximately 32 KDa. This molecular weight was reported in literature for the enzyme monomer (Wielgus-Kutrowska et al. 2014) and also in the data sheet of the recombinant purified human protein, used as internal standard that, as expected, showed an identical migration pattern (Fig. 1a1 ). Of note, there is the presence of a very low PNP amount in cell membranes that was unaffected by cell exposure to a specific phosphoinositolphospholipase C (PI-PLC, 10 units/mL, Molecular Probes, Eugene, OR, USA), and was able to hydrolyze the phospatidylinositol 4,5 diphosphate from glycosylphosphatidylinositol anchor protein (Menon 1994) , which could bind PNP to the plasma membranes (data not shown).
When C6 cell cytosol, membrane, and culture medium samples were reprobed with a specific antibody against bactin, a peculiar cytosolic protein, we found the exclusive presence of this protein in the electrophoretic lane corresponding to cell cytosol (Fig. 1a1) . This finding indicated that there was no cross-contamination between the membrane and cytosolic fractions and also suggested that extracellular PNP did not derive from dying cells. To better investigate this latter point, in parallel experiments, we assayed the LDH activity, assumed as an index of necrosis, in the culture medium removed at different times. As expected, no change in the enzyme activity was found throughout the observation period (Fig. 1a2) .
We also followed the time course of PNP release from C6 glioma cells in samples of medium removed at different times after its renewal. Densitometric analysis of immunoblots obtained by western blot analysis and compared to the amount of the internal standard assumed as 100% showed the presence of detectable amounts of PNP already at 30 min after medium replacement. Interestingly, extracellular PNP amount progressively increased along the observation period of 12 h, indicating the existence of a constitutive release of the enzyme (Fig. 1a3) . Characterization of the kinetic parameters of PNP derived from cytosol and culture medium of cultured C6 glioma cells The assay of the activity of PNP, present in the cytosol (Fig. 1b1 ) or in the culture medium (Fig. 1b2) , was carried out by using GUO as substrate and Pi as co-substrate. In both cases, the kinetic data fitted well to the Michaelis-Menten equation and allowed us to calculate the principal kinetic parameters. In both cases, the Michaelis-Menten constant (Km) for GUO was similar (about 28 lM), whereas the maximal rate of the Vmax value of the extracellular enzyme was about 10-fold lower than that measured for the cytosolic enzyme. This finding was compatible with the generally lower amount of PNP released in the culture medium than that present in the cytosol (Fig. 1a1) . As expected, when experiments were performed in the absence of Pi, an essential co-substrate for the enzyme reaction, no significant activity was detected.
To confirm the accuracy of our results, we performed a PNP mRNA silencing. RT-PCR showed that the enzyme expression was abolished in comparison with that revealed in wild-type or scrambled cells (Fig. 2a1) . Western blot analysis confirmed the reduction in the PNP production by PNPsilenced cells (Fig. 2a2 and a3) . Accordingly, the Vmax value was significantly reduced (by about 50%) in cytosol and medium samples from PNP-silenced cells in comparison to that evaluated in wild-type (control) and scrambledtransfected cells (Fig. 2b1 and b2) . Again, as expected, the removal of Pi in silenced cells completely abolished the enzyme activity.
Evaluation of the amount of PNP and purine compounds in the culture medium from C6 glioma cells after cell exposure to purine nucleotides or some purine receptor agonists Firstly, we tested the effect of the addition of ATP (10 lM) or GTP (10 lM) for 2 h to the culture medium on Kinetics parameters of PNP present in cell cytosol (b1) or released into the growth medium (b2) from rat C6 glioma cells grown in basal conditions. The kinetic parameters were calculated from the MichaelisMenten plots of the initial velocities of the PNP reaction versus guanosine (GUO) concentrations measured using aliquots of protein isolated from cytosol and growth medium. Reactions were conducted at 37°C for 15 min, and when present, Pi concentration was set to 50 mM. Values are the mean AE SEM from at least three different experiments, each run in duplicate. extracellular PNP and purine levels. Neither ATP nor GTP caused a significant change in the PNP extracellular levels (Fig. 3a) .
About 85% of ATP or GTP remained outside the cells. This quantity increased the amount of all extracellular purine compounds ( Fig. 3b1-b3 ) without modifying their profile. However, it should be emphasized that adding ATP or GTP modified only the levels of adenine-or guanine-based purines, respectively ( Fig. 3b1 and b2) . In contrast, the levels of XAN and UAc, which represent the final common pathway of the metabolism of adenine and guanine compounds, were increased by adding either ATP or GTP (Fig. 3b3) .
Then, we examined the effects of cell exposure to the selective stimulation of some metabotropic purine receptors, such as ATP P2Y 1 and adenosine A 2A receptors, on the extracellular amount of PNP and purines. These receptor subtypes, which are expressed by C6 glioma cells (Sabała et al. 2001; Castillo et al. 2008) , were chosen as prototypes of metabotropic purinoceptors, respectively, coupled to Gq or Gs proteins. The P2Y 1 or A 2A receptors stimulation for 2 h with MRS2365 (30 nM) or GS21680 (30 nM), respectively, provoked a similar effect causing a parallel and significant increase in the extracellular levels of PNP (Fig. 4a) and adenine-/guanine-based purines. Of note, all compounds (HYPO, GUA, XAN, and UAc) that are downstream of the PNP activity were significantly enhanced ( Fig. 4b1-b3 ). These effects were almost completely prevented by cell pre-treatment with 100 nM ZM241385 and 10 nM MRS2500, selective antagonists of A 2A R and P2Y 1 R, respectively (data not shown). Changes in the levels of PNP and purine compounds released from C6 glioma cells exposed to a reduced oxygen supply and re-oxygenation We exposed C6 glioma cells to a reduced O 2 (1%) supply for 2 h followed by 2 h re-oxygenation, thus mimicking a transient cerebral hypoxia. At the end of the hypoxia period (Fig. 5a) , the extracellular levels of PNP were significantly lower and those of the most part of extracellular adenine/ guanine-based compounds were higher than those measured, in the same period, in cells maintained in normoxic conditions (controls). In particular, the amount of ATP, GTP, ADO, GUO, HYPO, and GUA increased from about 3-to 12-fold, whereas that of INO increased up to about 200 times ( Fig. 5b1 and b2) . Conversely, the levels of XAN and UAc were approximately halved compared with controls (Fig. 5b3) . In contrast, at the end of the 2 h re-oxygenation period, we observed an increase in the extracellular PNP levels in comparison with those measured at the end of hypoxia (Fig. 5a) , whereas the levels of ADO, GUO, and INO were still higher than controls but significantly lower than those found at the end of hypoxia period. The amount of XAN, UAc, and especially HYPO was strongly increased compared to that measured in normoxic controls and even more in hypoxic cells (Fig. 5b1-b3 ). It should be noted that LDH activity, measured in the medium as percentage of the total enzyme activity, was not significantly modified at the end of the hypoxia (control: 4.3 AE 1.4%; hypoxia: 5.1 AE 1.8%) and re-oxygenation (control: 5.3 AE 1.9%; re-oxygenation: 6.1 AE 1.5%) periods.
Discussion
Purine nucleotides and nucleosides are important signal molecules that, interacting with a great number of ionotropic and metabotropic receptors, ensure homeostasis of vital cell functions (Burnstock 2006) . A balance among the levels of extracellular active purine compounds is maintained through the coordinate activity of metabolic pathways (Volont e and Fig. 3 Effect of cell exposure for 2 h to 10 lM ATP or guanosine triphosphate (GTP) on the extacellular level of phosphorylase (PNP) and the amount of purines released from C6 glioma cells. ATP or GTP were added to the medium 1 h after the end of the incubation period with labeled adenosine (ADO) or GUO (see Materials and methods section) and maintained along the subsequent 2 h. (a) The activity of PNP released in the extracellular medium was assayed using 200 lM guanosine (GUO) as substrate plus 50 mM Pi as co-substrate for 15 min at 37°C. Values are expressed as milli-International Units (mIU) of enzyme per mL of culture medium and are the mean AE SEM of three independent experiments, each run in duplicate. Panel b1-3: Aliquots of extracellular medium were assayed by HPLC analysis as described in Material and methods section. Values are expressed as nmoles/mL of medium and are the mean AE SEM of six independent experiments. *p < 0.05; **p < 0.01; ***p < 0.001: statistical significance vs. untreated (control) cells (Student's t test).
D'Ambrosi 2009
). The extracellular enzymes converting nucleotides into nucleosides are well characterized (Zimmermann et al. 2012) . They are mostly linked to the plasma membranes, even though microvesicle-mediated release of ectonucleotidases from cells composing the blood-brain barrier has been reported, especially when deprived of oxygen and glucose (Ceruti et al. 2011 ). Owing to their activity, the triphosphate nucleotides (ATP and GTP), released from cells, are converted into nucleosides. In contrast, the physiological fate of the extracellular nucleosides is, in addition to a receptormediated activity, to be taken up into the cells, where they represent the starting point of the so-called 'purine salvage pathway', aimed at preserving stable levels of intracellular triphosphate nucleotides (Fig. 6) . However, large amounts of purine bases and UAc are detectable, already in basal conditions, in the intercellular fluid, as we also found in C6 glioma cells. Therefore, we evaluated whether those compounds were transported outside the cells through carriers or originated from the extracellular metabolism of nucleosides.
As C6 cell pre-treatment with a cocktail of inhibitors of nucleosides/purine base carriers significantly increased the extracellular levels of purine bases and related metabolites without modifying the corresponding intracellular compounds (see table 1), we concluded that the extracellular purine bases mainly derived from the metabolism of extracellular nucleosides (ADO, INO, and GUO) escaped to the uptake.
Based on this evidence, we investigated whether extracellular enzymes specifically deputed to metabolize purine nucleosides were present in the culture medium. We focused on PNP, as it is the unique enzyme which, besides a wellknown influence on the immune system (Somech et al. 2013) , metabolizes, at the same time, compounds deriving from adenine-and non-adenine-based nucleotides, like INO and GUO, which, in mammalians, exert multiple neuroprotective effects (Hask o et al. 2004; Schmidt et al. 2007; Rathbone et al. 2008) .
Here, we demonstrated that: (i) cultured rat C6 glioma cells released PNP whose molecular weight was absolutely superimposable to that found in the cytosol of the same cells, (ii) the kinetics of the cytosolic and released enzymes, measured by using GUO as substrate, were very similar with an equivalent Km of about 28 lM, (iii) PNP, present in the extracellular medium, did not derive from cell lysis as ß-actin, a typical protein of cell cytoskeleton, was detectable in samples of cell cytosol and not of culture medium. We also excluded that extracellular PNP could derive from dead cells as the LDH activity, assumed as an index of cell necrosis, remained constant and at low levels along a period of 12 h. During this period, PNP accumulated in the culture medium suggesting that cells continuously release the enzyme in the absence of any significant protease activity. The transient silencing of the enzyme potently reduced its activity in cell cytosol and in extracellular medium, further confirming that rat C6 glioma cells, already in basal conditions, released a soluble and functionally active PNP, likely necessary to balance the extracellular purines, thus allowing a more correct functioning of their membrane receptors.
We also observed the presence of a very low amount of PNP in purified C6 cell membranes. We considered the hypothesis that, in analogy with ecto-nucleotidases, an ecto-PNP could exist. However, the computational prediction seems to exclude that the monomeric PNP is endowed with a glycosylphosphatidylinositol anchor (Hikezawa 2002) . Accordingly, cell treatment with PI-PLC, which makes water soluble a membrane-associated protein (Menon 1994) , was unable to modify PNP content in C6 glioma cell membranes. We hypothesize that the presence of PNP in cell membranes might be as a result of a process of the enzyme transport/ Fig. 5 Effect of the reduction in oxygen supply to 1% and of the subsequent reoxygenation on extracellular phosphorylase (PNP) levels and purine released from cultured C6 glioma cells. Cells were incubated for 30 min with unlabeled plus labeled ADO or GUO, necessary to evaluate the release of purines, as reported in the Materials and methods section. One hour after the end of the incubation period, cells were incubated in normal condition (control) or at a reduced rate (1%) of oxygen supply for 2 h (hypoxia). Subsequently, all cultures were maintained for further 2 h in normal oxygenation condition (Re-Ox). (a) Evaluation of PNP release carried out on aliquots suitably concentrated of medium removed from control cells and from cells at the end of both 1% O 2 exposure and re-oxygenation periods. The activity of released PNP was measured as reported in the previous figures and expressed as mIU/mL of medium. The values are the mean AE SEM from at least three different experiments, each run in duplicate. (b1-3) Purine release evaluated using aliquots removed from cultured cells after 2 h of cell exposure to normoxic or hypoxic conditions and at the end of the re-oxygenation period (2 h). Purine release was measured as reported in the previous figures. The values are expressed as nmoles/mL and are the mean AE SEM of six independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001: statistical significance versus control cells; release from inside to outside the cells. Indeed, our preliminary results showed that primary cultures of rat astrocytes and microglia release PNP through the lysosomal secretory pathway (personal observations).
Interestingly, the PNP release/activity may be variably modulated. First, we showed that adding to the culture medium of ATP or GTP did not significantly affect the PNP release, whereas the amount of all extracellular adenine-or guanine-based purines was increased by ATP or GTP, respectively, without modifying their proportions, as compared to those observed in basal conditions. Noteworthy, about 85% of exogenously added ATP or GTP was found in the medium, non-metabolized by extracellular nucleotidases, confirming that in C6 glioma cells the extracellular nucleotide metabolism is low (Wink et al. 2003) , and that 10 lM ATP or GTP are sufficient to decrease nucleotidase activity, thus triggering this self-limiting system for the nucleotide metabolism. Accordingly, we found (data not shown) that the intracellular levels of nucleosides, likely transported inside the cells, and nucleotides (formed as pointed out in the 'purine salvage pathways', Fig. 6 ) increased by 2-to 3-fold, and also in this case, without modifications in their proportions with respect to what we observed in resting condition (see cytosol values in the Table 1 ). These findings indicate that the machinery of the purine turnover worked at best without any imbalance to resynthesize purine nucleotides inside the cells. Also the extracellular PNP was sufficient to metabolize enhanced quantities of nucleosides formed by exogenously added nucleotides, contributing to maintaining balance in the whole system.
The results were different when cells were stimulated with selective agonists of some purine receptors (P2Y 1 and A 2A Fig. 6 Distribution of intra-and extracellular purines formed by the activity of cytosolic and extracellular enzymes. Our results demonstrated the presence of high levels of adenine and guanine bases, detectable outside the cells and formed thanks to the activity of so far unknown soluble enzymes similar to those involved in the metabolism and salvage pathway of intracellular purines. Among these, a key role discussed in this study is played by purine nucleoside phosphorylase (PNP) that catalyzes the phosphorolytic cleavage of inosine (INO) and guanosine (GUO) into the corresponding bases. Further abbreviations: ADA=ade-nosine deaminase; AdeSuc=adenyl-succinate synthase; HGPRT=hy-poxanthine/guanine ribosyltransferase; NSkase= nucleoside kinase; NTase=Nucleotidase; NTkase=Nucleotide kinase; 5-NTase=5 0 -ectonucleotidase; AMPDA = AMP deaminase; GUADA = guanine deaminase; XO = xanthine oxidase. Dotted arrow: to be demonstrated.
receptors), chosen as prototypal receptors acting via different transduction pathways, such as the Gq-mediated increase in intracellular Ca 2+ and the Gs-mediated cAMP formation, respectively (Sabała et al. 2001; Castillo et al. 2008) . The activation of these stimulatory receptors caused a simultaneous increase in the release of PNP as well as of adenine-and guanine-based purines. These findings are different from those obtained using ATP or GTP, which did not modify PNP release/activity. We suggest that these last compounds, able to interact with multiple receptors (i.e., ATP) or molecular pathways (i.e., GTP, for which specific receptors have not yet been identified), may influence the enzyme release/activity with multiple but opposite each other effects leading to a final null result. In contrast, findings obtained with cell stimulation by two selective receptor agonists (MRS2365 and CGS21680) suggests that differences in the signal transduction pathways activated by the stimulation of P2Y 1 or A 2A receptors, belonging to different families, are not crucial. Rather, it could be emphasized that: (i) the agonists of these receptors are not substrates of the enzymes deputed to purine metabolism, and (ii) they activate molecular machineries aimed at ensuring that the increase in the extracellular adenine-and guanine-based purines is accompanied by an appropriate pattern of enzymes involved in their metabolism.
On the other hand, cell exposure to a reduced O 2 supply for 2 h decreased the extracellular levels of PNP while increasing those of triphosphate nucleotides. However, such an increase was not massive as cells that compose the bloodbrain barrier, including astrocytes, release ecto-nucleotidases, which assure the breakdown of nucleotides released to toxic levels (Ceruti et al. 2011) . In relation to PNP, we cannot exclude that mechanisms supporting its release were altered by hypoxia that, however, did not affect cell viability (no modification in LDH release). Our findings could also suggest that, during hypoxia, the contemporaneous stimulation of different purinergic receptors/molecular machineries by nucleotides released at much lower levels than we exogenously administered to the cells or by nucleosides derived from their metabolism resulted in an overall PNP decreased activity. This condition allowed a longer permanence in the extracellular medium of GUO and INO, deriving from the metabolism of released nucleotides, which are considered neuroprotective compounds (Schmidt et al. 2007; Stone et al. 2009; Connell et al. 2013) and whose levels likely contribute to the inhibition of the activity of the xanthine oxidase and, as a consequence, the amount of XAN and uric acid. However, we should emphasize that the levels of the purine bases HYPO and GUA were also increased, indicating that PNP, although reduced, was functioning. In contrast, in the subsequent re-oxygenation period, we measured a significant increase in PNP activity over the basal levels. This led to the formation of greater amounts of XAN and uric acid, which commonly favor the formation of free radicals with dangerous (local and tissue) consequences, usually observed in the post-ischemia period (Cañas 1999) . Therefore, our data pointed out that it would be crucial to maintain the activity of PNP in a nearly 'constant' range, to avoid also the over-production of injuring metabolites.
Also it should be emphasized that we did not find variation in LDH activity in the medium at the end of the reoxygenation period. Thus, even though we cannot exclude a transient alteration in the cell membrane permeability, the increased extracellular PNP and purine amounts are likely as a result of the same mechanisms operating in basal condition.
In conclusion, our results demonstrated that PNP is not only a cytosolic enzyme but it can be released from cells (i.e., C6 glioma cells) into the growth medium, where it is metabolically active, causing a phosphorolytic cleavage INO and GUO into the corresponding bases. The monomer of the released (homotrimeric) PNP has a molecular weight similar to that of the cytosolic enzyme as well as the Km of the extracellular PNP was similar to that of the intracellular enzyme, whereas the Vmax was lower, likely because of the presence of a smaller amount of PNP in the medium in comparison to the cell cytosol. Interestingly, the constitutive PNP release from cells in basal condition was modulated by the selective activation of stimulatory metabotropic receptors for adenosine (A 2A ) or ATP (P2Y 1 ), that may physiologically occur, as the cell surrounding ATP concentration are sufficient for triggering purinergic responses (Yegutkin 2008) . Moreover, receptor stimulation can be triggered also by 'pathological-like' conditions such as hypoxia, in which variations in the amounts of extracellular purines play a role. In our opinion, an aspect that deserves further investigation is the modality of PNP release. In particular, it could be of interest to evaluate whether PNP is released as a soluble and/or a vesicular enzyme. As neurons seem not to be largely provided with this enzyme, it could be important to explore if soluble PNP released from surrounding glial cells might be of help in maintaining an homeostatic control of extracellular purines, thus limiting the exposure of neurons to eventual detrimental interactions of these agents with neuronal purinoceptors, whereas vesicular PNP could be captured by neurons, contributing to restore the intracellular pool of purine nucleotides and nucleosides. Thus, our findings suggest that extracellular PNP has novel functions, in particular in brain recovery after injury, and represent a starting point to elucidate further biological features of PNP, hitherto neglected.
